Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2013 Apr 15;62(5):505-8.
doi: 10.1097/QAI.0b013e318285cd33.

Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation

Michael J Vinikoor  1 , Anna Cope, Cynthia L Gay, Guido Ferrari, Kara S McGee, Joann D Kuruc, Jeffrey L Lennox, David M Margolis, Charles B Hicks, Joseph J Eron
Affiliations
Multicenter Study

Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation

Michael J Vinikoor et al. J Acquir Immune Defic Syndr. .

Abstract

Initiation of antiretroviral therapy during acute HIV-1 infection may prevent persistent immune activation. We analyzed longitudinal CD38+HLA-DR+ CD8+ T-cell percentages in 31 acutely infected individuals who started early (median 43 days since infection) and successful antiretroviral therapy, and maintained viral suppression through 96 weeks. Pretherapy a median of 72.6% CD8+ T cells were CD38+HLA-DR+, and although this decreased to 15.6% by 96 weeks, it remained substantially higher than seronegative controls (median 8.9%, P = 0.008). Shorter time to suppression predicted lower activation at 96 weeks. These results support the hypothesis that very early events in HIV-1 pathogenesis may result in prolonged immune dysfunction.

PubMed Disclaimer

Figures

Figure 1
Figure 1. CD8+ cell activation in AHI patients during 96 weeks of ART
Dynamics of CD8+ cell activation among 31 ART-treated acutely HIV infected individuals and comparison of 96 week activation levels to 30 seronegative controls.
See this image and copyright information in PMC

References

    1. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 infection. N Engl J Med. 2011;364:1943–1954. - PMC - PubMed
    1. Stacey AR, Norris PJ, Qin L, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol. 2009;83:3719–3733. - PMC - PubMed
    1. Gay C, Dibben O, Anderson JA, et al. Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy. PLoS One. 2011;6:e19617. - PMC - PubMed
    1. Deeks SG, Kitchen CMR, Liu L, et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood. 2004;104:942–947. - PubMed
    1. Fahey JL, Taylor JMG, Manna B, et al. Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. AIDS. 1998;12:1581–1590. - PubMed

Publication types

MeSH terms

LinkOut - more resources